secwatch.observer — SEC 8-K summary
======================================

Issuer:     DAXOR CORP (DXR)
CIK:        0000027367
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0001493152-23-042822
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Daxor allocates $550K of May 2023 offering proceeds to hematocrit capability development
--------------------------------------------------------------------------------

- Net proceeds of $3.56M from May 22, 2023 public offering of 410,260 shares at $9.75/share.
- $550,000 reserved for proprietary hematocrit capability for next-generation technologies.
- Development expected over 12 months, supported by Department of Defense efforts.
- Funds are part of the previously stated use of proceeds for next-gen technology development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/27367/000149315223042822/0001493152-23-042822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/27367/000149315223042822/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-042822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer